Medtronic (MDT) reported $7.92 billion in revenue for the quarter ended July 2024, representing a year-over-year increase of 2.8%. EPS of $1.23 for the same period compares to $1.20 a year ago.The reported revenue represents a surprise of +0.22% over the Zacks Consensus Estimate of $7.9 billion. With the consensus EPS estimate being $1.20, the EPS surprise was +2.50%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their n ...

Medtronic (MDT) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.50%. A quarter ago, it was expected that this medical device company would post earnings of $1.45 per share when it actually produced earnings of $1.46, delivering a surprise of 0.69%.Over the last four quarters, the co ...

Financial Performance - Medtronic's Q1 FY25 adjusted revenue reached $8.004 billion, reflecting a 5.3% organic growth[14, 46] - The adjusted diluted EPS was $1.23, showing a 7.5% increase in constant currency[14, 46] - The adjusted gross margin was 65.9%, up 30 bps year-over-year in constant currency[12, 46] - The operating margin was 24.4%, an increase of 60 bps year-over-year in constant currency[12, 46] - Operating cash flow was $1.0 billion, with a free cash flow of $0.5 billion[14] Segment Performance - Cardiovascular revenue reached $3.007 billion, with a 6.9% organic growth[14, 63] - Diabetes revenue was $647 million, demonstrating a 12.6% organic growth[14, 63] - Neuroscience revenue totaled $2.317 billion, reflecting a 5.3% organic growth[14, 63] - Medical Surgical revenue was $1.996 billion, with a 1.0% organic growth[14, 63] Guidance - Medtronic raised its FY25 organic revenue growth guidance to 4.5% to 5.0% from the previous 4.0% to 5.0%[12, 50] - The FY25 EPS guidance is $5.42 to $5.50[12, 51]

Exhibit 99.1 NEWS RELEASE Contacts: | --- | --- | |------------------|--------------------| | Erika Winkels | Ryan Weispfenning | | Public Relations | Investor Relations | | +1-763-526-8478 | +1-763-505-4626 | FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2025 financial results Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain ...

Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain StimulationGALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024.Key HighlightsRevenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as repo ...

Medtronic plc (MDT) is scheduled to report first-quarter fiscal 2025 results on Aug 20, before the opening bell.In the last reported quarter, the company’s adjusted earnings of $1.46 exceeded the Zacks Consensus Estimate by 0.69%. Medtronic beat estimates in each of the trailing four quarters, the average surprise being 4.48%.The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $7.90 billion, suggesting growth of 2.5% year over year. The consensus estimate for first-quarter earnings i ...

JHVEPhoto Medtronic (NYSE:MDT) continues to tread water as the broader market advances. The stock is up just 4% over the past 12 months, significantly underperforming the iShares U.S. Medical Devices ETF (IHI) which is higher by 10%. The Health Care Sector ETF (XLV) has returned better than 15% while the S&P 500 has beaten them all with a 28% performance from year-ago levels. I reiterate a buy rating on MDT, though. I see the stock as still undervalued today ahead of its Q1 2025 earnings report due out ...

Investment Thesis - Medtronic (MDT) is viewed as a low-volatility stock with solid dividend growth, maintaining a "Buy" rating despite a modest total return of 1.9% since mid-February [3] - The upcoming fiscal Q1 earnings report is anticipated on August 20, with expectations of revenue growth of approximately 2.5% year-over-year to $7.90 billion and flat adjusted EPS at $1.20 [5] Recent Earnings Performance - In the latest quarterly earnings released on May 23, MDT surpassed revenue and adjusted EPS consensus estimates, although it missed on GAAP EPS, with revenue showing a slight 0.5% year-over-year growth [4] Analyst Sentiment - Wall Street analysts have a bearish sentiment regarding the upcoming earnings, with 17 downgrade EPS revisions in the last 90 days [5] - Despite this, MDT has a strong earnings surprise record, with positive surprises in previous quarters [6] Dividend and Growth Prospects - MDT declared a quarterly dividend of $0.70, consistent with previous dividends, and received an upgrade from "Sell" to "Hold" by UBS analysts, driven by optimism in the diabetes segment [6] - The diabetes care devices industry is projected to grow at a 12.2% CAGR from 2024 to 2029, providing a favorable environment for MDT's diabetes business [6] FDA Approvals - MDT received FDA approval for its Simplera continuous glucose monitor and for asleep deep brain stimulation surgery, marking significant advancements in its product offerings [7] Valuation Metrics - MDT's share price increased by 3.7% over the last twelve months, with a 52-week range between $69 and $89, lagging behind the broader U.S. market and healthcare sector [8] - Valuation ratios are generally lower than MDT's historical averages, with a low "D" valuation grade assigned by Seeking Alpha Quant due to a high forward PEG ratio [8] Financial Projections - The dividend discount model (DDM) analysis suggests a fair price of $83.5 per share, indicating that MDT is approximately fairly valued [11] - A discounted cash flow (DCF) simulation estimates the business's fair value at around $118 billion, which is 10% higher than the current market cap, suggesting MDT is attractively valued based on future cash flows [13] Competitive Landscape - MDT faces fierce competition in the healthcare equipment industry, with competitors like Boston Scientific, Stryker, and Intuitive Surgical, which may impact investor perception [17] - Despite a larger revenue base, MDT's modest revenue growth compared to peers may affect its market valuation [20][22]

The office building of Medtronic Inc., an American medical technology company, is being pictured in ... [+] Shanghai, China, on July 23, 2024. (Photo by Costfoto/NurPhoto via Getty Images)NurPhoto via Getty ImagesMedtronic (NYSE: MDT) is scheduled to report its fiscal 2025 first-quarter results on Tuesday, August 20 (fiscal year ends in April). We expect Medtronic stock to trade higher post-Q1 results announcement, with its revenues and earnings expected to be slightly above the street estimates. The compan ...

GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividen ...